-
公开(公告)号：EP2948184A2
公开(公告)日：2015-12-02
申请号：EP15701106.5
申请日：2015-01-09
发明人： DOKTER, Willem , GOEDINGS, Peter Johannes , VERHEIJDEN, Gijsbertus Franciscus Maria , BEUSKER, Patrick Henry
IPC分类号： A61K47/48
CPC分类号： A61K47/60 , A61K9/19 , A61K45/06 , A61K47/6801 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6871 , A61K47/6889 , A61K2039/505 , C07K16/32 , C07K16/40 , C07K2317/24 , C07K2317/76
摘要： The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
-
公开(公告)号：EP3069735B1
公开(公告)日：2018-03-14
申请号：EP16160637.1
申请日：2015-01-09
发明人： DOKTER, Willem , GOEDINGS, Peter Johannes , VERHEIJDEN, Gijsbertus Franciscus Maria , BEUSKER, Patrick Henry
CPC分类号： A61K47/60 , A61K9/19 , A61K45/06 , A61K47/6801 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6871 , A61K47/6889 , A61K2039/505 , C07K16/32 , C07K16/40 , C07K2317/24 , C07K2317/76
摘要： The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
-
3.发明公开
公开(公告)号：EP3069735A1
公开(公告)日：2016-09-21
申请号：EP16160637.1
申请日：2015-01-09
发明人： DOKTER, Willem , GOEDINGS, Peter Johannes , VERHEIJDEN, Gijsbertus Franciscus Maria , BEUSKER, Patrick Henry
IPC分类号： A61K47/48
CPC分类号： A61K47/60 , A61K9/19 , A61K45/06 , A61K47/6801 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6871 , A61K47/6889 , A61K2039/505 , C07K16/32 , C07K16/40 , C07K2317/24 , C07K2317/76
摘要： The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
摘要翻译： 本发明涉及用于治疗表达HER2的人类实体瘤和血液系统恶性肿瘤，特别是乳腺癌，胃癌，膀胱癌，卵巢癌，肺癌，前列腺癌， 胰腺癌，结肠直肠癌，头颈部鳞状细胞癌或骨肉瘤，以及急性淋巴细胞白血病。 具体而言，本发明涉及用于治疗具有HER2 IHC 2+或1 +和HER2 FISH阴性组织状态的人类实体瘤的含有杜洛霉素的ADCs。 有利地，本发明涉及用于治疗三阴性乳腺癌（TNBC）的含有杜洛霉素的ADC。
-
4.发明授权DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY 有权DUOCARMYCIN-ADCS MIT VERBESSERTER IN-VIVO-ANTITUMORWIRKUNG
公开(公告)号：EP2948184B1
公开(公告)日：2016-03-23
申请号：EP15701106.5
申请日：2015-01-09
发明人： DOKTER, Willem , GOEDINGS, Peter Johannes , VERHEIJDEN, Gijsbertus Franciscus Maria , BEUSKER, Patrick Henry
IPC分类号： A61K47/48
CPC分类号： A61K47/60 , A61K9/19 , A61K45/06 , A61K47/6801 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6871 , A61K47/6889 , A61K2039/505 , C07K16/32 , C07K16/40 , C07K2317/24 , C07K2317/76
摘要： The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
摘要翻译： 本发明涉及用于治疗人类实体瘤和表达HER2，特别是乳腺癌，胃癌，膀胱癌，卵巢癌，肺癌，前列腺癌等的血液恶性肿瘤的含有duocarmycin的抗体 - 药物偶联物（ADC） 胰腺癌，结肠直肠癌，头颈鳞状细胞癌或骨肉瘤，急性淋巴细胞白血病。 特别地，本发明涉及用于治疗具有HER2 IHC 2+或1+和HER2 FISH阴性组织状态的人实体瘤的含二焦虑霉素的ADC。 有利地，本发明涉及用于治疗三阴性乳腺癌（TNBC）的含有二焦虑素的ADC。
-
-
-
搜索结果
4 条记录 (耗时 0.009 秒)
